Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Adenosine; Ticagrelor

Criteria

Inclusion Criteria:

• Suitable for ECG recording of CBFV and have no adverse reaction to adenosine challenge

• Have a body mass index between 18 and 30 kg/m2

Exclusion Criteria:

• History of clinically significant disease or disorder.

• Abnormal vital signs